Por Gabriel Francisco Leonardos
25 de abril de 2011
Anti-Counterfeiting 2012
Legal framework
The growth of the Brazilian market and economy is parallelled by the increase of counterfeiting activities. The enforcement of IP rights involves planning, technology, intelligence, training and coordination, with support from a number of laws and treaties, as well as the relevant rules of the Federal Constitution, the Civil Code, the Criminal Code, the Civil Procedure Code, the Criminal Procedure Code and administrative statutory instruments. The legal framework for anticounterfeiting includes:
• the Industrial Property Law (Law 9,279/96);
• the Copyright Law (Law 9,610/98); and
• the Software Law (Law 9,609/98).
In addition, Brazil is a signatory to the main international IP instruments, such as:
• the Paris Convention for the Protection
of Industrial Property (as reviewed in Stockholm in 1967);
• the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs);
• the Berne Convention for the Protection of Literary and Artistic Works;
• the Washington Copyright Convention;
• the Universal Copyright Convention;
• the Rome Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organisations; and
• the Geneva Convention for the Protection of Producers of Phonograms
against Unauthorised Duplication of Their Phonograms.
Últimas notícias por Gabriel Francisco Leonardos
12 de fevereiro de 2026
Kasznar Leonardos é ranqueado no Chambers Global Guide 2026
Temos a honra de anunciar que Kasznar Leonardos foi reconhecidos pelo Chambers and Partners Global Guide 2026. Por mais um ano, o … Kasznar Leonardos é ranqueado no Chambers Global Guide 2026
26 de janeiro de 2026
Canetas emagrecedoras do Paraguai são consideradas falsas
Com a febre do uso das canetas emagrecedoras no Brasil e o alto custo do tratamento, tornou-se cada vez mais comum buscar … Canetas emagrecedoras do Paraguai são consideradas falsas
17 de dezembro de 2025
Ozempik: STJ decide que patente expirará em 2026, abrindo caminho para versões genéricas
A 4ª Turma do Superior Tribunal de Justiça (STJ) vetou o pedido da Novo Nordisk pela expansão do prazo da patente da … Ozempik: STJ decide que patente expirará em 2026, abrindo caminho para versões genéricas